FDA Approves Repeat Treatment for iDose TR Glaucoma Implant
Glaukos receives FDA approval allowing patients to receive multiple iDose TR treatments for glaucoma management, expanding treatment options.
Glaukos receives FDA approval allowing patients to receive multiple iDose TR treatments for glaucoma management, expanding treatment options.
Glaukos shares fell 9% after Q4 iDose sales growth disappointed investors, though the company maintained its 2026 revenue guidance of $600-620 million.
Wells Fargo raises Glaukos price target to $120, citing Epioxa as underappreciated growth catalyst beyond iDose focus. Stock upgrade to Overweight.